Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira Enrolls Patients in New Ebola Drug Trial

Premium

Tekmira Pharmaceuticals this week announced that it has dosed the first patients in a phase I trial of its next-generation Ebola virus drug TKM-Ebola.

The company is developing the drug under a contract from the US Department of Defense that could be worth up to $140 million and fund the drug's development through to commercialization. Tekmira had previously tested an earlier version in phase I, but cut that trial short in order to incorporate improvements to its lipid nanoparticle delivery vehicles.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.